Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Rhea-AI Summary

Decoy Therapeutics (Nasdaq: DCOY) announced a strategic partnership with Quantori, supported by funding from Google Cloud, to build a Google Cloud-native, AI-driven peptide design and molecular simulation platform.

The production-grade, GPU-accelerated platform will integrate folding models, molecular dynamics, and Decoy's IMP³ACT engine, targeting a ~25- to 100-fold increase in computational throughput to accelerate antiviral peptide discovery.

Positive

• Expected computational throughput uplift of 25–100× for peptide design
• Partnership includes Google Cloud funding to support infrastructure
• Deployment of a fully containerized, GPU-accelerated architecture (Q-Suite)
• Integration of platform with Decoy's IMP³ACT design-build-test-learn engine

Negative

• None.

News Market Reaction – DCOY

-4.84% 15.9x vol

8 alerts

-4.84% News Effect

+4.4% Peak Tracked

-27.4% Trough Tracked

-$224K Valuation Impact

$4M Market Cap

15.9x Rel. Volume

On the day this news was published, DCOY declined 4.84%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.4% during that session. Argus tracked a trough of -27.4% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $224K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 15.9x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Design bandwidth increase: 25-100x Throughput increase: 25- to 100-fold

2 metrics

Design bandwidth increase 25-100x Expected boost in computational peptide design bandwidth from new platform

Throughput increase 25- to 100-fold Anticipated increase in computational throughput from integrated Google Cloud-native environment

Market Reality Check

Price: $7.62 Vol: Volume 30,649 is 2.13x th...

high vol

$7.62 Last Close

Volume Volume 30,649 is 2.13x the 20-day average of 14,422, indicating elevated trading interest before this news. high

Technical Shares at $8.26 are trading below the 200-day MA of $9.09 and sit 51.18% under the 52-week high of $16.92.

Peers on Argus

No peers from the Pharmaceutical Preparations sector appeared in the momentum sc...

No peers from the Pharmaceutical Preparations sector appeared in the momentum scanner, suggesting DCOY’s -4.07% move was stock-specific rather than part of a sector-wide move.

Historical Context

5 past events · Latest: Mar 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Reverse stock split	Negative	-11.3%	Announced 1-for-12 reverse split to address Nasdaq minimum bid requirement.
Feb 11	Investor communication	Positive	-3.0%	Joined Webull Corporate Connect platform to enhance news and disclosure distribution.
Feb 05	Investor webinar	Positive	-1.6%	Participated in Webull webinar highlighting antiviral peptide conjugate therapeutic programs.
Feb 04	Gates GACA update	Positive	-7.6%	Investor segment explaining Global Access Commitment Agreement and IMP3ACT manufacturing plans.
Jan 13	Gates GACA deal	Positive	+53.4%	Global Access Commitment with Gates Foundation to fund scalable peptide-conjugate platform.

Pattern Detected

Recent corporate and partnership-style news has often been met with negative or muted price reactions, with the notable exception of the Gates Foundation agreement, which saw a strong positive move.

Recent Company History

Over the last few months, Decoy has undergone a significant transition, including a name change, Nasdaq relisting efforts, and a planned reverse stock split announced on Mar 5, 2026. Strategic visibility and investor outreach increased through Webull’s platforms and virtual events in February 2026. A key milestone was the Global Access Commitment Agreement with the Gates Foundation on Jan 13, 2026, which drew a 53.37% price gain. The current AI-driven peptide design partnership aligns with this strategy of leveraging advanced platforms to accelerate antiviral development.

Market Pulse Summary

This announcement details a partnership with Quantori, backed by Google Cloud funding, to build an i...

Analysis

This announcement details a partnership with Quantori, backed by Google Cloud funding, to build an integrated AI-driven peptide design and molecular simulation platform aiming for a 25- to 100-fold increase in computational throughput. It extends Decoy’s broader strategy of using advanced computation to accelerate D-MAV antiviral discovery, building on prior platform initiatives with the Gates Foundation. Investors may watch for concrete pipeline milestones, such as new peptide candidates entering development, and how efficiently this infrastructure plugs into the existing IMP³ACT engine.

Key Terms

protein folding, molecular dynamics simulations, high-performance computing, gpu-accelerated, +3 more

7 terms

protein folding medical

"integrates advanced protein folding models, molecular dynamics simulations"

Protein folding is the natural process where a long chain of building blocks in a protein bends and twists into a specific three-dimensional shape that determines what the protein does, much like folding a sheet of paper into a particular origami shape to make a crane or a box. For investors, folding matters because the correct shape affects a drug’s effectiveness, safety, stability and manufacturing yield, so problems with folding can raise development risk, regulatory hurdles and commercial uncertainty.

molecular dynamics simulations medical

"integrates advanced protein folding models, molecular dynamics simulations"

Molecular dynamics simulations are computer-based 'movies' that model how atoms and molecules move and interact over time, letting scientists watch how a drug candidate, protein, or material behaves at a tiny scale. For investors, these simulations matter because they help predict whether a molecule will be stable, bind to a target, or perform as intended—reducing experimental time, lowering development cost and scientific uncertainty that affect timelines, funding needs and risk.

high-performance computing technical

"Cloud-native infrastructure, advanced machine learning and high-performance computing"

A cluster of very powerful computers, special chips and fast networks designed to tackle huge, complex calculations far faster than a normal PC — like replacing a single delivery van with a synchronized fleet to move a city’s worth of packages. For investors, high-performance computing matters because it enables faster product development, more accurate simulations and data analysis, and new revenue streams for hardware, software and services, making firms that supply or use it potentially more competitive and scalable.

gpu-accelerated technical

"deploy a fully containerized, GPU-accelerated computational architecture"

Using graphics processing units (GPUs) to run compute‑heavy tasks much faster than standard central processors by handling many small operations at once. For investors, GPU‑acceleration can shorten time to insight and lower costs for advanced workloads like artificial intelligence, large‑scale data analysis, or simulations, potentially boosting product performance, enabling new services, and improving competitive position—think switching from a bicycle to a high‑speed train for moving large data loads.

diffusion-based conformational ensemble generation medical

"Diffusion-based conformational ensemble generation to improve structural plausibility"

A computational method that uses diffusion-style algorithms to generate a range of likely three-dimensional shapes a biological molecule (often a protein) can adopt. Think of it like taking a crumpled piece of paper and running many slow, guided simulations to see how it might smooth out and refold into different forms. For investors, this matters because faster, more reliable predictions of molecular shapes can speed drug discovery, reduce laboratory costs and uncertainty, and help companies value or de-risk research programs more quickly.

generative ai technical

"integrate emerging protein design models, generative AI techniques, and experimental data"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

reverse protein folding medical

"support forward and reverse protein folding workflows, enabling both structure prediction"

Reverse protein folding, often called the inverse protein folding problem, is the process of designing a linear amino-acid sequence that will reliably fold into a predetermined three-dimensional protein shape. For investors, it matters because it underpins computational protein design—like specifying the blueprint to build a custom tool—enabling faster creation of new drugs, enzymes, or diagnostics and potentially reducing time and cost to bring biologic products to market.

AI-generated analysis. Not financial advice.

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x

CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically increase the speed and scale of antiviral peptide discovery.

"At its core, this collaboration is about speed," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "By working with Quantori and leveraging Google Cloud's scalable infrastructure, we are building a foundation that will allow Decoy to fundamentally accelerate the pace at which we can design new peptides. This will result in a dramatic improvement in our ability to explore chemical space, iterate on designs and translate computational insights into real therapeutic candidates. This will be foundational to realizing the intent of D-MAVs – single antiviral drugs that are effective against multiple viruses for both prevention and treatment, thus addressing multiple valuable commercial opportunities and important public health use cases in one drug program."

The collaboration will deliver a production-grade, cloud-based infrastructure built on Google Cloud Platform that integrates advanced protein folding models, molecular dynamics simulations and performance optimization tools into a single scalable environment. The new platform is designed to integrate Cloud-native infrastructure, advanced machine learning and high-performance computing directly into Decoy's proprietary IMP³ACT™ design-build-test-learn engine. By unifying these capabilities into a single production-grade computational environment, Decoy expects to increase computational throughput by approximately 25- to 100-fold, enabling a step-change improvement in how rapidly new peptide candidates can be conceived, optimized and advanced. Additionally, the modularity of the platform will allow Decoy to continually adapt and upgrade its capabilities in the fluid competitive space of AI-driven molecular design.
The architecture also lays the foundation for a new generation of AI-enabled research tools that can integrate emerging protein design models, generative AI techniques, and experimental data streams into Decoy's discovery workflows.

"This platform also provides a flexible capability to easily integrate novel design algorithms and models, which, as we all know, continue to evolve rapidly," said Dr. Barbara Hibner, Chief Scientific Officer. "In addition, it enables the seamless incorporation of our proprietary structure-function data – which we are very good at generating - directly into the peptide design process to drive the design models of both today and the future."

"Decoy's IMP³ACT platform represents an exciting application of modern computational biology," said Yuriy Gankin, Chief Scientific Officer of Quantori. "By combining scalable cloud infrastructure, advanced molecular simulation workflows, and Quantori's Q-Suite accelerators, we aim to create a platform that dramatically expands the speed and scale of peptide discovery."

Under the agreement, Quantori will deploy a fully containerized, GPU-accelerated computational architecture powered by components of its Q-Suite engineering platform. These accelerators enable rapid integration of AI models, scalable high-performance computing workflows, and production-grade scientific applications tailored to the needs of computational drug discovery.

The platform will support:

• Tiered protein folding pipelines, enabling dynamic trade-offs between speed and structural accuracy
• Advanced molecular dynamics simulations with GPU acceleration and AI-enhanced sampling
• Diffusion-based conformational ensemble generation to improve structural plausibility
• Automated algorithm selection and precision optimization to balance computational efficiency and model fidelity
• Real-time monitoring, visualization of 3D structures and performance benchmarking through a unified interface

The unified environment will support forward and reverse protein folding workflows, enabling both structure prediction and design applications. Integration with molecular dynamics pipelines will allow Decoy to move seamlessly from sequence generation to structural validation and conformational analysis within a single orchestrated system.

The initiative builds on Decoy's existing momentum in applying an engineering mindset to drug discovery and reflects the Company's broader strategy of leveraging advanced computation to reduce the time, cost and risk associated with developing peptide-conjugate therapeutics.

About Quantori

Quantori is an accelerator-powered digital engineering and AI solutions services company focused exclusively on the life sciences and healthcare industries. The company develops advanced scientific software platforms, data infrastructure, and AI-enabled research tools that accelerate drug discovery and R&D operations. Quantori's Q-Suite platform provides modular software accelerators that enable rapid development of cloud-native scientific systems integrating machine learning, high-performance computing, and experimental data pipelines.

Learn more at www.quantori.com or follow Quantori on LinkedIn.

About Decoy Therapeutics, Inc.

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (DMAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP³ACT platform, which combines AI-enabled design and rapid synthesis, Decoy develops antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment. The Company's lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease.

Learn more at decoytx.com and connect with the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk  that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Current Report on Form 8-K filed on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.   

View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform-302710286.html

SOURCE Decoy Therapeutics, Inc

FAQ

How much faster will Decoy Therapeutics (DCOY) design peptides with the new Quantori platform?

The platform is expected to increase computational throughput by approximately 25–100×. According to the company, that speed-up should let Decoy explore chemical space and iterate designs far more rapidly, advancing candidates from in silico design to validation faster.

What role does Google Cloud funding play in Decoy Therapeutics' (DCOY) new peptide design platform?

Google Cloud funding supports building a production-grade, cloud-native infrastructure. According to the company, funding enables scalable GPU resources, managed services, and cloud integration that underpin high-throughput AI-driven peptide discovery and simulation.

Which capabilities will Quantori deliver to Decoy Therapeutics (DCOY) under the partnership?

Quantori will provide a containerized, GPU-accelerated computational architecture and Q-Suite accelerators. According to the company, this includes folding pipelines, AI-enhanced molecular dynamics, diffusion-based ensembles, and real-time visualization for integrated discovery workflows.

How will the new platform affect Decoy Therapeutics' (DCOY) IMP³ACT discovery engine?

The platform will integrate cloud-native ML and HPC directly into IMP³ACT to enhance design cycles. According to the company, this integration is intended to improve iteration speed, structural validation, and the translation of computational designs into experimental candidates.